Physician profile
Gregory Sensenich
NPI 1669441531
$2,670.70
in general payments reported to CMS, 2019-2025
30 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $447 · 2021: $626 · 2022: $300 · 2023: $305 · 2024: $288 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.90 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $308.52 | 2021-2024 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $278.89 | 2019-2024 | Breztri |
| Pfizer INC. | $203.53 | 2019-2021 | |
| Lilly USA, LLC | $197.94 | 2019-2023 | Mounjaro |
| Sunovion Pharmaceuticals INC. | $195.01 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $192.87 | 2021-2024 | Austedo Xr |
| Novo Nordisk INC | $186.44 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $136.34 | 2019-2024 | Spravato |
| Amgen INC. | $124.05 | 2019-2025 | Repatha, Otezla, Repatha |
| Mylan Specialty L.P. | $108.95 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $79.58 | 2020-2023 | Eliquis |
| Astellas Pharma US INC | $72.79 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $70.06 | 2023-2025 | Rexulti, Abilify Maintena |
| Sumitomo Pharma America, INC. | $67.25 | 2023-2025 | Gemtesa, Aptiom |
| Esperion Therapeutics, INC. | $50.97 | 2021-2025 | Nexletol |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $46.02 | 2024-2025 | Fanapt, Hetlioz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.98 | 2019-2020 | |
| Allergan, INC. | $44.39 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.83 | 2023-2024 | Caplyta |
| Exact Sciences Corporation | $28.87 | 2023-2024 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $27.35 | 2025 | |
| Merck Sharp & Dohme LLC | $26.98 | 2020-2021 | |
| Philips North America LLC | $26.23 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.79 | 2019 | |
| Eisai INC. | $22.87 | 2021 | |
| Sun Pharmaceutical Industries INC. | $18.53 | 2021 | |
| Abbott Laboratories | $15.71 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.86 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.18 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Sensenich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.